ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Move to accelerate cancer care expansion across India
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
At the core of Verida is Spectral Precise Image technology paired with a third-generation Nano-panel Precise dual-layer detector and an AI-based deep learning reconstruction engine
The investment case for health technology in India is frequently overstated in one direction and understated in another
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
Subscribe To Our Newsletter & Stay Updated